Crossmark

Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma

Crossref DOI link: https://doi.org/10.1186/s13014-019-1427-5

Published Online: 2019-12-12

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lewitzki, Victor https://orcid.org/0000-0001-9146-3083
Klement, Rainer J. https://orcid.org/0000-0003-1401-4270
Kosmala, Rebekka

Lisowski, Dominik

Flentje, Michael

Polat, Bülent
Funding

Funding for this research was provided by:

Deutsche Forschungsgemeinschaft (funding program Open Access Publishing)

University of Wuerzburg (funding program Open Access Publishing)
License Information

Text and Data Mining valid from 2019-12-01

Version of Record valid from 2019-12-12
More Information

Article History

Received: 18 September 2019

Accepted: 22 November 2019

First Online: 12 December 2019

Ethics approval and consent to participate

: This retrospective study does not need a special approval by the local ethics committee of the University of Würzburg (reference Nr. 20190822 01).

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below